Oncotarget

Researchers explore the role of cancer stemness in drug resistance of colorectal cancer cells. They found that a triple combination treatment against BRAF, EGFR, and MEK significantly reduced stemness and oncogenic signaling pathways in these cells.

Researchers discuss the potential of targeting STAT3 as a therapeutic approach for pediatric H3K27M-mutant DMGs, a challenging type of brain tumor with limited treatment options.

This podcast explores the genetic factors that contribute to early breast cancer in the Kazakh population, highlighting the importance of personalized risk assessment. The study identifies specific variants in cancer predisposing genes, providing valuable insights for genetic testing.

In this podcast, researcher Meghan J. Price discusses UDP-glucose dehydrogenase (UGDH) and its role in tumor progression. The review paper explores UGDH as a molecular indicator of tumor progression, its involvement in cancer signaling pathways, and potential therapeutic targets and prognostication markers.

Researchers Monal Patel and Marcus E. Peter from Northwestern University discuss an ancient anti-cancer mechanism called DISE that senses mutational load in cancerous cells. They explore its potential in cancer treatment by targeting essential survival genes.

The podcast discusses the risks faced by patients with hematologic malignancies in relation to COVID-19, including poor response to vaccination. It addresses concerns about outdoor activities and large gatherings, emphasizing the importance of balancing infection risk with social isolation challenges.

Researchers investigate links between endometrial cancer and polycystic ovary syndrome through transcriptomic analysis, exploring upregulation of the IGF-1 gene in PCOS endometrium and proposing a transcriptomic atlas for uncovering molecular mechanisms.

Learn about the potential of targeting fatty acid binding proteins (FABPs) as a therapeutic approach for multiple myeloma (MM), including their impact on MYC oncogene expression, mitochondrial function, DNA methylation patterns, and immune cell infiltration. FABPs, specifically FABP5, show promise as potential biomarkers and therapeutic targets for MM, improving patient outcomes.

Researchers discuss the potential repurposing of DPP4 inhibitors for target therapy resistance in renal cell carcinoma, focusing on their impact on Sunitinab efficacy.

The podcast discusses the development of a real-time live tissue sensitivity assay for pancreatic adenocarcinoma, focusing on predicting patients' response to chemotherapy using fresh tumor samples. It highlights the potential for personalized treatment strategies and improved disease-free survival with sensitive adjuvant regimens.